![](https://ahip.imgix.net/images/Message-Guide-Pages-High-Priced-Drugs-01.jpg?auto=format%2Ccompress&crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=422&ixlib=php-3.3.1&w=750&s=f693a8918ae98a3dbc86f5929ad18fa5)
All News
![](https://ahip.imgix.net/images/Message-Guide-Pages-High-Priced-Drugs-01.jpg?auto=format%2Ccompress&crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=422&ixlib=php-3.3.1&w=750&s=f693a8918ae98a3dbc86f5929ad18fa5)
![](https://ahip.imgix.net/images/RxPrices.png?auto=format%2Ccompress&crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=563&ixlib=php-3.3.1&w=750&s=8e69c39699f67b9a9552b83e6790f38d)
![](https://ahip.imgix.net/images/OrphanDrugs.jpg?auto=format%2Ccompress&crop=focalpoint&fit=crop&fp-x=0.6321&fp-y=0.4874&h=500&ixlib=php-3.3.1&w=750&s=c2b1b18845820f72e5c7bc852e8db528)
Sticker Shock: New Research Shows an Average List Price Increase of Over 200% for Top Part D Drugs
Research released by AARP’s Public Policy Institute (PPI), list prices for the top 25 Medicare Part D drugs have increased by an average of 226%.
Getting the Facts: Drug Companies Increasingly Using Patent Games to Avoid Competition
A recent article published by STAT highlights how Big Pharma is using continuation patents to keep lower-cost generic drugs from reaching the market.
New Health Affairs Study: Competition In Pharmaceuticals Leads to Lower Prices, Reduced Drug Spending
A study published in Health Affairs found that new brand-name pharmaceutical competition resulted in decreases in net prices of existing drugs.